Research programme: interleukin-1 receptor-associated kinase 4 inhibitors - Ligand Pharmaceuticals/TG Therapeutics

Drug Profile

Research programme: interleukin-1 receptor-associated kinase 4 inhibitors - Ligand Pharmaceuticals/TG Therapeutics

Alternative Names: IRAK-4 inhibitors - Ligand Pharmaceuticals/TG Therapeutics; LG-0224912

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Ligand Pharmaceuticals; TG Therapeutics Inc
  • Class Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Arthritis; Autoimmune disorders
  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
  • 20 Apr 2015 Pharmacodynamics data from a preclinical trial in B-cell lymphoma released by TG Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top